Compare · NAUT vs RVTY
NAUT vs RVTY
Side-by-side comparison of Nautilus Biotechnology Inc. (NAUT) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAUT and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.19B, about 37.8x NAUT ($296.1M).
- Over the past year, NAUT is up 201.3% and RVTY is up 8.0% - NAUT leads by 193.3 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- RVTY has more recent analyst coverage (19 ratings vs 7 for NAUT).
PerformanceNAUT+201.34%RVTY+8.03%
2025-06-09+0.00%2026-06-08
- Company
- Nautilus Biotechnology Inc.
- Revvity Inc.
- Price
- $2.32-3.13%
- $100.33+1.92%
- Market cap
- $296.1M
- $11.19B
- 1M return
- -19.72%
- +1.48%
- 1Y return
- +201.34%
- +8.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 2
- Recent ratings
- 7
- 19
NAUT
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest NAUT
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Large owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)
- SEC Form DEFA14A filed by Nautilus Biotechnology Inc.
- SEC Form DEF 14A filed by Nautilus Biotechnology Inc.
- SEC Form 10-Q filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Reports First Quarter 2026 Financial Results
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
- Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
- Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)